Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.61 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.55 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.48 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.48 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.48 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488829 | 1.00 | MET (0.61) | METMAP4K3MAP4K2MAP3K1AAK1 | |
| SCHEMBL488728 | 0.92 | MET (0.55) | METMAP4K3MAP4K2MAP3K1AAK1 | |
| SCHEMBL30453768 | 0.92 | MET (0.55) | METMAP4K3MAP4K2MAP3K1AAK1 | |
| SCHEMBL30453421 | 0.89 | MET (0.75) | METMAP4K3MAP4K2MAP3K1AAK1 | |
| SCHEMBL488385 | 0.89 | MET (0.75) | METMAP4K3MAP4K2MAP3K1AAK1 | |
| SCHEMBL489251 | 0.88 | MET (0.64) | METMAP4K3MAP4K2MAP3K1AAK1 | |
| SCHEMBL30454392 | 0.88 | MET (0.64) | METMAP4K3MAP4K2MAP3K1AAK1 | |
| SCHEMBL1900138 | 0.88 | MAP4K3 (0.62) | METMAP4K3MAP4K2MAP3K1AAK1 | |
| SCHEMBL3243135 | 0.88 | MAP4K3 (0.62) | METMAP4K3MAP4K2MAP3K1AAK1 | |
| SCHEMBL13276216 | 0.87 | MET (0.56) | METMAP4K3MAP4K2MAP3K1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |